Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
RA Capital Management and affiliated funds report beneficial ownership of 12,896,519 shares of Vor Biopharma common stock, equal to 19.9% of the company. This stake is calculated against 54,185,582 shares outstanding as of March 30, 2026.
The position consists of 2,567,245 shares held directly by RA Capital Healthcare Fund and a mix of Common Stock Warrants for 1,056,072 shares and Pre-Funded Warrants for 10,000,000 shares, plus small option-related holdings. A “Beneficial Ownership Blocker” in the Pre-Funded Warrants limits exercise so the fund cannot exceed 19.99% ownership.
The fund reported recent open-market sales of 458,411 shares on April 17, 2026 at a weighted average price of $16.28 per share and 171,963 shares on April 20, 2026 at a weighted average price of $15.77 per share, as well as vesting of stock options with a $12.80 exercise price.
Vor Biopharma Inc. reported that an investment vehicle associated with RA Capital executed open-market sales of its Common Stock. On April 17, 2026, the RA Capital Healthcare Fund LP sold 458,411 shares at a weighted average price of $16.28 per share, in multiple trades between $15.95 and $16.85.
On April 20, 2026, the Fund sold an additional 171,963 shares at a weighted average price of $15.77 per share, with individual trades between $15.75 and $16.00. Following these transactions, the Fund held 2,567,245 shares of Vor Biopharma common stock indirectly, and RA Capital Management, its general partner and principals disclaim beneficial ownership beyond their pecuniary interests.
RA Capital Management and affiliated funds report beneficial ownership of 12,739,024 shares of Vor Biopharma common stock, representing 19.9% of the outstanding shares as of March 30, 2026. This percentage is based on 54,185,582 shares outstanding, adjusted for warrants and options exercisable within 60 days.
The position is held primarily through RA Capital Healthcare Fund, which owns 3,197,619 common shares, Common Stock Warrants for up to 1,056,072 shares, and Pre-Funded Warrants for up to 10,000,000 shares, plus small option positions held by Joshua Resnick and Andrew Levin for RA Capital’s benefit. Warrant “Beneficial Ownership Blockers” limit exercises above 9.99% for the Common Stock Warrants and above 19.99% for the Pre-Funded Warrants.
Recent activity includes open market sales by the Fund of 530,610 shares at a weighted average price of $16.15 on April 13, 2026, 153,735 shares at $15.97 on April 14, 2026, and 53,644 shares at $16.01 on April 15, 2026.
Vor Biopharma Inc. insider entities associated with RA Capital reported open-market sales of an aggregate 737,989 shares of Common Stock over three days at weighted average prices around $16 per share. The shares are held directly by RA Capital Healthcare Fund, L.P., for which RA Capital Management, L.P. is investment manager.
After these transactions, the reporting entities continue to hold 3,197,619 shares of Vor Biopharma common stock indirectly. RA Capital Management, its general partner, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest.
Vor Biopharma Inc. shareholder RA Capital Management and affiliates report beneficial ownership of 12,554,642 shares of common stock, representing 19.9% of the class. This stake includes common shares, common stock warrants and pre-funded warrants, all subject to “beneficial ownership blocker” limits that cap how many shares can be exercised. The filing notes recent open market sales by RA Capital Healthcare Fund totaling over 600,000 shares around $16–$17 per share, while RA Capital-affiliated managers also hold vested stock options in the company for its benefit.
RA Capital Healthcare Fund LP, an entity associated with RA Capital Management, reported open-market sales of Vor Biopharma common stock over three days. The filings show indirect sales totaling 620,133 shares of Common Stock on April 8–10, 2026, at weighted average prices between $15.75 and $16.98 per share, executed in multiple trades within those ranges. After these transactions, the reporting group indicates indirect ownership of 3,935,608 shares. The Adviser, its general partner, the Fund, and individuals Peter Kolchinsky and Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Vor Biopharma Inc. filed an initial ownership report for Chief Medical Officer Jeremy Brett Sokolove. He holds employee stock options to acquire 130,100 shares of common stock at an exercise price of $8.18 per share, expiring on October 31, 2035, with vesting beginning November 1, 2026 and continuing over the following three years. He also reports direct ownership of 27,900 shares of common stock, alongside restricted stock units that vest starting November 1, 2026, with remaining units vesting quarterly over three years, all subject to his continued service.
RA Capital Management and related parties report beneficial ownership of 12,399,706 shares of Vor Biopharma common stock, representing 19.9% of the class. This percentage is based on 54,185,582 shares outstanding as of March 30, 2026 and includes certain exercisable warrants and stock options.
The position reflects shares and warrants held primarily by RA Capital Healthcare Fund, including common stock warrants for up to 1,056,072 shares and pre-funded warrants for up to 10,000,000 shares, both subject to “beneficial ownership blocker” provisions that cap exercisability. Recent activity includes several open market sales by the Fund on April 2 and April 6, 2026 at weighted average prices between $16.25 and $19.09 per share.
RA Capital Healthcare Fund LP, through RA Capital Management, reported open-market sales of Vor Biopharma common stock. On April 2 and April 6, the Fund sold a total of 849,257 shares at prices ranging from $16.25 to $19.09 per share, using weighted-average pricing for each trade block.
After these transactions, the Fund indirectly held 4,555,741 Vor Biopharma shares, with RA Capital Management and related principals disclaiming beneficial ownership beyond their pecuniary interests. All reported holdings are described as being held directly by the Fund.
Vor Biopharma Inc. joint Schedule 13G filing reports that investment vehicles affiliated with TCG and Reporting Individual Chen Yu beneficially hold equity positions representing 10.5% (5,673,078 shares) of Vor's Common Stock. The filing bases the percentage on 54,185,582 shares, calculated from 48,847,504 shares outstanding as of March 23, 2026 plus 5,338,078 shares issued in an underwritten offering that closed March 30, 2026.